Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Apr 13, 2022 11:45am
76 Views
Post# 34600564

RE:RE:Stutters thinks he's a performer ... hahaha

RE:RE:Stutters thinks he's a performer ... hahahaAbsolutely wrong Stutter - I started buying ATE in late 2017.

Why on earth would you start making up dates - to who's benefit ?  What are you (a newbie) trying to prove here?  Just foolish.

----------------------

Anyway ... I'm here for the big prize and I'm waiting.
Will I get it?  I can't tell you that.

But ... I simply love the P2 A/B data and I see how it applies in the future.  I see the 4 building blocks and how they apply to the funnel.

Sure, we run into liver confusion around day 25ish ... big deal ... that's what a once/week just might fix.  Regardless - the money just may come from acute before it comes from anywhere.

By the time we are potentially selling 346 acute - we just might be selling other stuff ... you just never know.

Anyway - Stutters is looking for a dividend cheque and a defined growth from this company but sadly - he doesn't realize a development company doesn't work like that on the markets.

Seriously - if you don't know how to value a development company, stop trying to apply cash-cow principles to it.  It's rather embarassing to see you all frustrated over a share price that means nothing on the daily.  Especially when it's only retail investors involved.  Focus on the H2S.

I know - patience isn't your forte ... but ... if you're going to hang around development companies and you're going to sh&t your drawers on every penny movement - you're in the wrong place amigo.

Time to rethink your interests.

Seriously ... rethink your stock interests.

Crusty old men should not be buying risky drug developers - you really should know that.

: )

<< Previous
Bullboard Posts
Next >>